

CLAIMS

1. Immediate-release pharmaceutical or nutraceutical micronized powder having a particle size of at most 5 100 μm and comprising the combination of at least one active substance, at least one wetting agent and at least one diluent.
2. Powder according to Claim 1, characterized in that 10 it has a particle size of at most 50 μm .
3. Powder according to Claim 1, characterized in that it has a particle size of at most 10 μm .
- 15 4. Powder according to any one of Claims 1 to 3, characterized in that it allows the dissolution of all of the active substance(s) in less than 30 seconds, when it is administered mucosally.
- 20 5. Powder according to any one of Claims 1 to 4, characterized in that the active substance is in a micronized form.
- 25 6. Powder according to any one of Claims 1 to 5, characterized in that the active substance is selected from the group consisting of cyproterone acetate, norethisterone acetate, progesterone, 3-keto-desogestrel, norgestimate, laevonorgestrel, desogestrel, gestodene, natural estrogens such as 30 estradiol and derivatives thereof, synthetic estrogens such as ethinylestradiol, Δ -4-androstenedione, testosterone, dihydrotestosterone or androstanolone, DHEA, trinitrine, fentanyl, nitroglycerine, nicotine (nicotine S(-)), 35 scopolamine, clonidine, isosorbide dinitrate,

5 alclometasone dipropionate, phloroglucinol,
 molsidomine, acetazolamide, acyclovir, adapalene,
 alclomethasone dipropionate, amcinonide, ameline,
 bamethan sulphate + escin, betamethasone valerate,
 betamethasone dipropionate, bufexamac, caffeine,
 calcipotriol monohydrate, cetrimonium bromide,
 clobetasol propionate, crilanomer, desonide,
 dexpanthenol, diclofenac, diflucortolone, valerate,
 difluprednate, diphenyldramine hydrochloride,
 10 econazole nitrate, erythromycin, flumetasone
 pivalate, fluocinolone acetonide, fluocinodine,
 fluocortolone, fluocortolone hexanoate,
 fluocortolone pivalate, hydrocortisone,
 hydrocortisone acetate, ibacitabine, ibuprofen,
 15 imiquimod, ketoconazole, ketoprofen, lidocaine,
 metronidazole, miconazole nitrate, minoxidil,
 nifluminic acid, penciclovir, benzoyl peroxide,
 piroxam, iodinated povidone, promestriene,
 pyrazinobutazone, roxithromycin, sulphacetamide,
 20 triamcinolone, tazarotene, tretinoin and
 isotretinoin, triclocarban, vidarabine
 monophosphate, β -3-adrenergic agonist, growth
 hormone, oxybutinin, buprenorphine, pergolide,
 nestorone, 7α -methyl-19-nortestosterone,
 25 mecamylamine, salbutamol, clenbuterol, selegiline,
 buspirone, ketotifen, lidocaine, ketorolac,
 eptazocine, insulin, α -interferon, prostaglandins,
 5-aminolevulinic acid, benzodiazepine alprozolam,
 diclofenac, fenoprofen, flubiprofen, ketoprofen,
 30 methyl phenidate, miconazole, piroxicam,
 bruprenorphine, alprozolam, dexmedetomidine,
 prazosin (α -adrenergic antagonist), alprostadil,
 tulobuterol (β -adrenergic agonist), ethinyl
 oestradiol + norelgestromin, ketorolac,
 35 physostigmine, medindolol (α -adrenergic agonist),

rotigotine (dopamine D2 antagonist), thiatolserine, Esomeprazole, Melagatran (in the case of thrombosis), Rosuvastatin, Ezetimide, Pitavastatin (hyperlipidaemia), Mitiglinide (type II diabetes),
5 Cilomilast, Viozan (asthma), Aripipazole (psychiatry), Omapatrilat (hypertensive), Orzel (cancerology), Caspofungin acetate, Voriconazole (infections), new COX inhibitors such as Etoricoxib (inflammation), Valdecoxib (arthritis) and Parecoxib, Substance P antagonist (depression),
10 Darifenacin (urology), Eletriptan (migraine), Alosetron, Tegaserod, Capravirine (HIV), Finasteride (5-alpha reductase inhibitor) and combinations thereof.

15 7. Powder according to any one of Claims 1 to 6, characterized in that the active substance(s) is (are) selected from the group comprising vitamins, inorganic salts, and brewer's yeast.

20 8. Powder according to any one of Claims 1 to 7, characterized in that the wetting agent is selected from polyols such as sorbitol, or glycerin, PEG, hexylene glycol, triacetin, hydrogenated vegetable oils such as hydrogenated castor oil, polyoxy(ethylene)polyoxy(propylene) copolymers such as Lutrol® F68, polyoxyethylene alkyl ethers such as the Cremophor®, and mixtures thereof.

25 30 9. Use of a powder according to any one of Claims 1 to 8, characterized in that the diluent is selected from the group consisting of calcium or sodium carbonate or bicarbonate, sucrose, mannitol, xylitol, sorbitol, lactose, maltitol, glucose, cellulose or microcrystalline cellulose powder,
35

starch and its derivatives, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol and mixtures thereof.

5

10. Powder according to any one of Claims 1 to 9, characterized in that it further comprises an antistatic agent.

10 11. Powder according to Claim 10, characterized in that the antistatic agent is selected from the group consisting of colloidal silica, magnesium silicate, talc, calcium silicate and tribasic calcium phosphate and mixtures thereof.

15

12. Powder according to any one of Claims 1 to 11, characterized in that it further comprises a binder which may be selected from the group consisting of acacia, alginic acid, carboxymethyl cellulose sodium, microcrystalline cellulose, dextrins, ethyl cellulose, gelatin, glucose, guar gum, hydroxypropyl methyl cellulose, methyl cellulose, polyethylene oxide, povidone, pregelatinized starch and mixtures thereof.

25

13. Powder according to any one of Claims 1 to 12, characterized in that it further comprises an absorption enhancer selected from the group consisting of aliphatic fatty acid esters such as isopropyl myristate, fatty acids such as oleic acid; alcohols or polyols, such as ethanol, propylene glycol and polyethylene glycol; the components of essential oils and terpen derivatives (such as eugenol, geraniol, nerol, eucalyptol, menthol); surfactants, preferably non ionic, such as

30

35

polyoxyethylene sorbitan (fatty acid ester),
polyoxyethylene alkyl ether, polyoxyethylene derived
from castor oil; moisturizers such as glycerin,
urea; keratolytic agents, such as alpha-hydroxy
5 acids (lactic acid, citric acid, etc), 23-lauryl
ether, aprotinin, azone, benzalkonium chloride,
cetylpyridinium chloride, cetyltrimethylammonium
bromide, cyclodextrins, dextran sulphate, lauric
acid, lysophosphatidylcholine, menthol,
10 methoxysalicylate, methyl oleate, oleic acid,
phosphatidylcholine, polyoxyethylene, polysorbate
80, sodium EDTA, sodium glycocholate, sodium
glycodeoxycholate, sodium lauryl sulphate, sodium
salicylate, sodium taurocholate, sodium
15 taurodeoxycholate, sulphoxides, alkyl glycosides and
mixture thereof.

14. Powder according to any one of Claims 1 to 13,
characterized in that it further comprises an
20 edulcorant agent and/or a flavoring agent.
15. Powder according to Claim 14, characterized in that
the edulcorant agent is selected from the group
consisting of aspartam, dextrates, dextrose,
25 fructose, mannitol, sodium or calcium saccharinate,
sorbitol, sucralose, sucrose, and mixtures thereof.
16. Powder according to Claim 14, characterized in that
the flavoring agent is selected from the group
30 consisting of flavors of synthetic, semi-synthetic
or natural origin, such as for example mint,
peppermint, lemon, banana, strawberry, raspberry,
mandarin, orange, vanilla, passion fruit, caramel,
and the mixtures thereof.

17. Powder according to any one of Claims 1 to 16, characterized in that it is in a form suitable for its application on the buccal mucosa, the nasal mucosa or the vaginal mucosa.

5

18. Powder according to any one of Claims 1 to 14 characterized in that it is in a form suitable for its application to the buccal mucosa sublingually.

10 19. Powder according to any one of Claims 1 to 18, characterized in that it is in a sprayable form.

15 20. Powder according to any one of Claims 1 to 18, characterized in that it is packaged in a single-dose packet.

21. Powder according to any one of Claims 1 to 18, characterized in that it is packaged in a thermally moulded capsule provided with a peelable operculum.

20

22. Powder according to any one of Claims 1 to 18, characterized in that it is in a packaging suitable for powder administration known to those skilled in the art.

25

23. Use of a powder according to any one of Claims 1 to 20, for making a immediate-release pharmaceutical or nutraceutical composition.